Pros | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Among most bought funds within the category. | ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | ![]() 5Y returns in the bottom 25% of the category. ![]() 3Y returns in the bottom 25% of the category. |
INDMoney rank | 3/8 | 7/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 7 Years | 12 Years | ||
Fund Size | 6104 Cr | 8737 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 1.04% | 0.89% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 39 | 41 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (11.69%) Dr Reddy's Laboratories Ltd (8.85%) Divi's Laboratories Ltd (8.13%) Cipla Ltd (7.54%) Aurobindo Pharma Ltd (5.71%) | Sun Pharmaceuticals Industries Ltd (12.22%) Divi's Laboratories Ltd (7.55%) Lupin Ltd (5.93%) Cipla Ltd (5.69%) Dr Reddy's Laboratories Ltd (5.69%) | ||
No of Sectors | 3 | 1 | ||
Top 3 Sectors | Health (96.53%) Basic Materials (2.35%) Financial Services (1.11%) | Health (100%) | ||
Equity % | 95.89% | 99.45% | ||
Debt % | - | - | ||
P/E | 32.47 | 37.97 | ||
P/B | 4.4 | 6.05 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 0.19% | 0.06% | ||
3-Month Return | 3.31% | 1.2% | ||
6-Month Return | 15.86% | 11.11% | ||
1-Year Return | 4.33% | -0.73% | ||
3-Year Return | 29.38% | 24.25% | ||
5-Year Return | 22.62% | 20.09% |
Sharpe | 1.31 | 1.06 | ||
Alpha | 4.41 | 0.66 | ||
Beta | 0.94 | 0.91 | ||
Standard Deviation | 15.52 | 15.05 | ||
Information Ratio | 1.42 | -0.24 |
Description | ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Dharmesh Kakkad,Sharmila D’mello | Sailesh Raj Bhan,Kinjal Desai |